556104-39-3

Upstream product

• 53872-16-5 4-Carbomethoxy-5-methoxy-2-(4'-methoxyphenyl)oxazole 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 620-05-3 iodomethylbenzene 
• 65299-01-6 acetic acid 2-benzyloxy-5-formylphenyl ester 
• 65298-99-9 acetic acid 5-formyl-2-hydroxy-phenyl ester 
• 821006-09-1 (4S,5R)-5-(3-acetoxy-4-benzyloxyphenyl)-2-(4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxylic acid methyl ester 
• 556104-38-2 (4R,5R)-5-(3-acetoxy-4-benzyloxyphenyl)-2-(4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxylic acid methyl ester 

Downstream Products

• 556104-48-4 {[(3R,4S,7S,10S,11R)-15-Benzyloxy-10-(benzyloxycarbonyl-methyl-amino)-3-ethyl-11-hydroxy-7-isopropyl-3-methyl-6,9-dioxo-2-oxa-5,8-diaza-bicyclo[10.3.1]hexadeca-1⁽¹⁶⁾,12,14-triene-4-carbonyl]-amino}-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

Total synthesis of ustiloxin D and considerations on the origin of selectivity of the asymmetric allylic alkylation

As part of investigations into cell cycle checkpoint inhibitors, an asymmetric synthesis of the antimitotic natural product, ustiloxin D, has been completed. A salen-Al-catalyzed aldol reaction was employed to construct a chiral oxazoline 9 (99% yield, 98

Enantioselective total synthesis of ustiloxin D

Ustiloxin D and phomopsin A are potent antimitotic agents that bind to tubulin and interfere with cellular microtubule function. A synthetic strategy has been developed to allow access to both of the natural products as well as a variety of variants of th